Authors: Shahin Akhondzadeh Mehdi Shafiee Sabet Mohammad Hossein Harirchian Mansoreh Togha Hamed Cheraghmakani Soodeh Razeghi Seyyed Shamssedin Hejazi Mohammad Hossein Yousefi Roozbeh Alimardani Amirhossein Jamshidi ShamsAli Rezazadeh Aboulghasem Yousefi Farhad Zare Atbin Moradi Ardalan Vossoughi
Publish Date: 2009/10/20
Volume: 207, Issue: 4, Pages: 637-643
Abstract
Fiftyfour Persianspeaking adults 55 years of age or older who were living in the community were eligible to participate in a 22week doubleblind study of parallel groups of patients with AD The main efficacy measures were the change in the Alzheimer’s Disease Assessment Scale—cognitive subscale and Clinical Dementia Rating Scale—Sums of Boxes scores compared with baseline Adverse events AEs were systematically recorded Participants were randomly assigned to receive a capsule saffron 30 mg/day 15 mg twice per day or donepezil 10 mg/day 5 mg twice per daySaffron at this dose was found to be effective similar to donepezil in the treatment of mildtomoderate AD after 22 weeks The frequency of AEs was similar between saffron extract and donepezil groups with the exception of vomiting which occurred significantly more frequently in the donepezil groupThis phase II study provides preliminary evidence of a possible therapeutic effect of saffron extract in the treatment of patients with mildtomoderate Alzheimer’s disease This trial is registered with the Iranian Clinical Trials Registry IRCT138711051556N1
Keywords: